Aqua Lymphatic Therapy in Women Who Suffer from Breast Cancer Treatment-related Lymphedema: a Randomized Controlled Study
Overview
Oncology
Authors
Affiliations
Background: Lymphedema is an adverse effect of breast cancer surgery. Aqua lymphatic therapy (ALT) is a novel treatment for limb volume reduction.
Objective: The aim of this study was to examine whether ALT is a safe method and whether there are differences in adherence, limb volume, and quality of life between women who perform only self-management treatment and women who participate as well in ALT.
Design: Design of the study was single-blind randomized clinical trial.
Setting: The setting was in a hydrotherapy pool, 1.2 m depth, and a temperature of 32-33 degrees capital ES, Cyrillic.
Patients: Forty-eight women (56 +/- 10 years), with a 12.8% lymphedema relative volume, participated in the study.
Intervention: The control group was instructed to perform the self-management treatment. The study group joined a weekly session of ALT for 3 months in addition to the self-management therapy.
Measurements: Adherence was assessed by a self-reported diary, limb volume by a water displacement device, quality of life by the Upper Limb Lymphedema Questionnaire (ULL27), prior to, and after the intervention period.
Results: There was no episode of arm infection or aggravation in limb volume during the study period. ALT had a positive, statistically and clinically significant immediate effect on limb volume but no long-term effect was noted. The adherence rate to ALT was significantly higher than the adherence to self-management therapy. QOL improved in the study group.
Conclusion: ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema. A significant immediate and insignificant long-term effect on limb volume was noted.
The Effect of Exercise on Reducing Lymphedema Severity in Breast Cancer Survivors.
Lian Y, Sandhu S, Asefa Y, Gupta A Cancers (Basel). 2024; 16(7).
PMID: 38611045 PMC: 11011010. DOI: 10.3390/cancers16071367.
Munoz-Alcaraz M, Jimenez-Vilchez A, Perula-de Torres L, Serrano-Merino J, Garcia-Bustillo A, Pardo-Hernandez R Healthcare (Basel). 2023; 11(18).
PMID: 37761765 PMC: 10531370. DOI: 10.3390/healthcare11182568.
Anuszkiewicz K, Jankau J, Kur M Breast Cancer. 2022; 30(2):187-199.
PMID: 36571707 PMC: 9950281. DOI: 10.1007/s12282-022-01428-z.
Wang J, Chen X, Wang L, Zhang C, Ma J, Zhao Q PLoS One. 2022; 17(8):e0272337.
PMID: 35921372 PMC: 9348687. DOI: 10.1371/journal.pone.0272337.
Reger M, Kutschan S, Freuding M, Schmidt T, Josfeld L, Huebner J J Cancer Res Clin Oncol. 2022; 148(6):1277-1297.
PMID: 35171330 PMC: 9114041. DOI: 10.1007/s00432-022-03947-w.